Skip to main content
Premium Trial:

Request an Annual Quote

New Recommendations for Testing Diabetes Drugs

In the wake of safety questions over GlaxoSmithKline's Avandia, FDA is recommending more rigorous testing of diabetes drugs for heart attack and stroke risk. The new recommendations are effective immediately, reports the Wall Street Journal, and they suggest that clinical trials should be redesigned with heart attack and stroke risk assessment in mind, and that any cardiovascular events that occur during the trial should be reviewed by independent, blinded cardiologists. Another recommendation is that the trials include older and sicker patients who should then be followed for a longer period of time.

The Scan

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.